Fennec Pharmaceuticals Inc. (FENC)
Fennec Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Research Triangle Park, NC, US. The stock last traded at $12.03, down 5.87% on the session, giving a market capitalisation of $417.9M. On trailing twelve-month figures it carries a trailing P/E of -39.17, a net margin of -16.4%. Its beta of 1.07 implies it has historically moved more than the broad market.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc. is most often compared with the following Healthcare names: